Position in NGEN
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$559,656
New position
Shares Held
271,678
first reported quarter
Ownership
0.253%
of shares outstanding
% of Portfolio
0.43%
of 13F equity value
Holder Rank
#9
of 62 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Stonepine Capital Management, LLC holds $108,574,607 across 61 Biotechnology names. NGEN ranks #40 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VSTM |
Verastem, Inc.
|
3,349,627 | $12,795,575 | |
| 2 | TENX |
Tenax Therapeutics, Inc.
|
660,000 | $9,603,000 | |
| 3 | NKTR |
Nektar Therapeutics
|
120,654 | $8,422,855 | |
| 4 | ADMA |
Adma Biologics, Inc.
|
740,000 | $6,193,800 | |
| 5 | CAMP |
Camp4 Therapeutics Corp
|
1,389,622 | $6,072,648 | |
| 6 | ELOX |
Eloxx Pharmaceuticals, Inc.
|
397,160 | $5,512,580 | |
| 7 | KZIA |
Kazia Therapeutics Ltd
|
345,179 | $4,860,120 | |
| 8 | CRBP |
Corbus Pharmaceuticals Holdings, Inc.
|
425,000 | $3,986,500 |
All Filings in NGEN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $559,656 | 271,678 | Shares | Sole | 2026-08-17 | |
| No filing history on record for this holder in this stock. | ||||||